Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
108.3 USD | -1.23% | +1.14% | -11.93% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company returns high margins, thereby supporting business profitability.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-11.93% | 6.75B | C+ | ||
+25.61% | 660B | C+ | ||
+25.87% | 562B | B | ||
-5.24% | 358B | C+ | ||
+16.49% | 322B | B- | ||
+8.28% | 297B | C+ | ||
+7.09% | 219B | B+ | ||
-9.12% | 196B | A+ | ||
+5.01% | 199B | B- | ||
-8.75% | 149B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- JAZZ Stock
- Ratings Jazz Pharmaceuticals plc